Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 7/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 3/20 | 0.38 |
| ▸ | ATRIP | Q8WXE1 | 3/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HPN | P05981 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23037655 | 0.82 | GRM2 (0.40) | GRM2PRMT5WDR77TLR8TLR7 | |
| SCHEMBL23037646 | 0.79 | NLRP3 (0.49) | NLRP3TLR8TLR7CYP1A2 | |
| SCHEMBL30837706 | 0.79 | NLRP3 (0.49) | NLRP3TLR8TLR7CYP1A2 | |
| SCHEMBL29314789 | 0.78 | TLR8 (0.47) | NLRP3TLR8TLR7 | |
| SCHEMBL23037642 | 0.78 | NLRP3 (0.53) | NLRP3TLR8TLR7CYP1A2 | |
| SCHEMBL23037625 | 0.77 | NLRP3 (0.49) | NLRP3GRM2ATRATRIPROCK2 | |
| SCHEMBL23037569 | 0.75 | NLRP3 (0.47) | NLRP3GRM2ATRATRIPROCK2 | |
| SCHEMBL29314786 | 0.75 | TLR8 (0.52) | NLRP3TLR8TLR7CYP1A2 | |
| SCHEMBL23037603 | 0.74 | NLRP3 (0.41) | NLRP3GRM2ATRATRIPROCK2 | |
| SCHEMBL20651728 | 0.74 | NLRP3 (0.47) | NLRP3GRM2ATRATRIPROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4353235-A2 | NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-3784670-A1 | NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | NLRP3 1/4885GRM2 1735/4885ATR 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.